Ключевые слова:
истинная полицитемия, JAK2 V617F, тромбоз, миелопролиферативные неоплазии, гиперкоагуляция, мутационный анализ, аллельная нагрузка.Библиографические ссылки
Barbui T., Tefferi A., Vannucchi A.M. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol. 2021; 96(1):144–162. https:// doi.org /10.1002/ajh.26028
Buxhofer-Ausch V., Kralovics R. JAK2-mutated myeloproliferative neoplasms: genetic underpinnings and clinical implications. Curr Hematol Malig Rep. 2021; 16(1):28–38. https://doi.org/10.1007 /s11899-020-00596-7
Gangat N., Tefferi A. Myeloproliferative neoplasms in 2022: current controversies and evolving treatment algorithms. Best Pract Res Clin Haematol. 2022; 35(1):101319. https://doi.org/10.1016/j. beha.2022.101319
Griesshammer M., Gisslinger H., Mesa R.A. Current and future treatment options for polycythemia vera. Ann Hematol. 2023;102(1):1–12. https:// doi.org/10.1007/s00277-022-05048-9
Grinfeld J., Nangalia J., Green A.R. Molecular pathogenesis of myeloproliferative neoplasms: JAK2 and beyond. Hematology Am Soc Hematol Educ Program. 2021; 2021(1): 61–69. https://doi.org/ 10.1182/hematology.2021000223
Marchetti M., Barbui T. Thrombosis in myeloproliferative neoplasms: pathogenetic facts and unresolved issues. Clin Lymphoma Myeloma Leuk. 2020; 20(10):600–606. https://doi.org/10.10 16/j.clml.2020.03.015
Pemmaraju N., Kantarjian H.M., Verstovsek S. Novel therapies for myeloproliferative neoplasms: beyond JAK2 inhibitors. Blood Rev. 2021;47:100775. https://doi.org/10.1016/j.blre.2020.100775
Randi M.L., Rinaldi V., Scapin M., et al. Thrombotic complications in patients with polycythemia vera: JAK2 mutation and beyond. Blood Transfus. 2022; 20(3):193–202. https://doi.org/10 .2450/2021.0154-21